challenge, with manufacturing mostly concentrated in the US and Europe for high-value mRNA vaccines, and China and India for … traditional platforms and high-volume production. Countries with domestic COVID-19 vaccine manufacturing capacity prioritized … region to be self-sufficient in vaccine research and manufacturing to effectively address future pandemics and build regional …